New BCR/Abl Inhibitor from Ariad Pharmaceuticals

Ponatinib (AP24534) Pivotal Trial in Drug-Resistant or Intolerant Chronic Myeloid Leukemia Ariad's new drug for CML is now in clinical trial and has Orphan drug status from FDA and EMA. www.ariad.com